援助如何运作
通过无与伦比的全方位服务便利性，简化患者的专业药房体验
-
1. 检查您的保险范围/福利验证
我们的专业出纳员团队会找到最佳的保险途径，以最大程度地减少自付费用。
-
2. 将处方转移到 AmeriPharma®
我们与您之前的药房或处方人员合作来处理您的处方，使过渡变得快速而简单。
-
3. 事先授权
我们的专家团队将在 24 至 72 小时内获得您保险公司的批准。
-
4. 共付额援助和经济援助
我们确保患者获得经济援助，并降低共付额、自付费用和高额免赔额。迄今为止，AmeriPharma® 专科护理已为患者争取到 1TP4.4755 亿美元的经济援助。
-
5.护理协调
AmeriPharma® 在安排和协调我们的专业护士为您进行家庭输液时，会将您的日程安排和家庭环境放在首位。
-
6. 交付协调
药品始终严格遵守运输的具体要求。次日或隔夜冷链配送将根据您的时间安排进行协调。
What Is Zirabev?
Zirabev is an anticancer drug with an active component, “bevacizumab-bvzr.” It is used to treat several types of cancer. Zirabev belongs to the class of vascular endothelial growth factor (VEGF) inhibitors that targets VEGF proteins and blocks their activity. In cancer patients, the VEGF proteins overexpress and are typically involved in forming new blood vessels within the cancer cells to provide cells with oxygen and other nutrients needed for their growth and uncontrolled division.
In 2019, the FDA approved Zirabev as a biosimilar version of Avastin (an already FDA-authorized biological drug) as it has the active substance, “bevacizumab.” Compared to Avastin, Zirabev offers the same effectiveness, works the same way, and shows the same side effects.
What is Zirabev Used To Treat?
Metastatic Colorectal Cancer (mCRC)
Metastatic colorectal cancer is an advanced form of cancer that initially began in the colon or rectum but has spread to other body areas. If a patient has not previously been treated, Zirabev is used as a first-line treatment in combination with fluorouracil-based chemotherapy.
In other cases, if the patient has been treated previously with bevacizumab (Zirabev, Avastin, or Mvasi), and their cancer did not respond well, Zirabev is then used as second-line treatment in combination with chemotherapy.
Metastatic Renal Cell Carcinoma (mRCC)
Zirabev is used in combination with interferon-alpha to treat patients who have metastatic renal cancer (kidney cancer that has spread to other areas).
Ovarian Cancer
Ovarian cancer represents a group of cancer that begins in the women’s ovaries and spreads to other areas, such as the fallopian tube and the peritoneum.
Patients with this cancer are typically treated with Zirabev in combination with chemotherapy drugs (paclitaxel and carboplatin), followed by Zirabev alone.
If a patient’s cancer is sensitive to platinum-based chemotherapy or comes back after six months, Zirabev is first used in combination with chemotherapy agents (paraplatin and either paclitaxel or gemcitabine), followed by Zirabev as a single-agent therapy.
Metastatic Cervical Cancer
In this cancer, Zirabev is used in combination with chemotherapy agents (topotecan and paclitaxel or cisplatin and paclitaxel).
Non-squamous, Non-small Cell Lung Cancer
Zirabev is used as a first-line treatment combined with chemotherapy agents (paclitaxel and carboplatin) in patients whose tumor is metastatic, persistent, and unresectable (the cancer cannot be removed via surgery).
Recurrent Glioblastoma
Zirabev is used as a single agent to treat glioblastoma, an aggressive form of brain and spinal cord cancer.
共付额和经济援助
AmeriPharma™ 专业药房减轻患者及其家人的经济负担
-
先进的软件可以定位资金来源，为您匹配高额的基金会项目
-
我们的一位共付额援助专家将协助您完成申请流程
-
自动更新信息将发送给您和您的医生，告知您资金状况
How Does Zirabev Work?
Zirabev works to slow down the growth of cancers. It contains an active component, “bevacizumab-bvzr,” which is a recombinant monoclonal (IgG1) antibody designed to recognize and bind to VEGF proteins (that typically encourages the blood vessel’s formation to provide cancer with essential nutrients to grow and divide).
Upon binding to VEGF protein, it inhibits VEGF activity. As a result, the blood vessels do not grow within the cancer cells. Due to a lack of nutrients and oxygen supply, cancer cells starve and do not progress further.
Dosage Form and Strength
Zirabev is available in a single-dose vial that is administered intravenously. The single-dose vial is available in:
- 100 mg/4 ml strength (contains 25 mg bevacizumab-bvzr/ml)
- 400 mg/16 ml strength (contains 25 mg bevacizumab-bvzr/ml)
Precaution
Zirabev therapy is not for everyone. You should consult your healthcare provider before taking Zirabev therapy if you:
- 是 pregnant, as this drug causes embryo-fetal toxicity and can harm your unborn baby.
- 是 planning to become pregnant. If you’re receiving Zirabev treatment, then you must use birth control.
- 是 breastfeeding or planning to breastfeed. Since the data on Zirabev secretion in breast milk is limited, avoiding Zirabev is recommended.
- Have a previous history of hypertension, heart failure, kidney disease, and diabetes or have undergone surgery recently.
Zirabev Side Effects
Every patient reacts differently while receiving Zirabev IV infusions. Some of the common side effects they may experience during or after Zirabev infusion includes:
- Headache, backache
- 高血压
- Inflammation of skin and nose
- Taste changes
- Watery eyes
- Bleeding or nose bleeding
- 皮肤干燥
- Cough, vomiting, or nausea
- 食欲不振
Zirabev also has some severe and potentially fatal side effects which demand immediate medical attention, such as:
- Gastrointestinal perforation
- Posterior reversible encephalopathy syndrome
- 肾衰竭
- Complications in wound healing
- Infusion-related reactions causing hypertension, tremors, trouble breathing, and chest pain
- 充血性心力衰竭
- Arterial thromboembolism
- Embryo-fetal toxicity
- Stroke or heart problem
- Venous thromboembolic events
- Ovarian failure
接受保险
我们接受 Medicare、跨州 Medicaid、Medi-Cal、Blue Shield 以及大多数私人保险。请致电我们，了解更多您的保险信息。
Chinese 
English 
Spanish 
Arabic 
Armenian 
Amharic 
Myanmar 
Korean 
Romanian 
Russian 
Swahili 
Tagalog 
Vietnamese 
Nepali 
Pashto